Search Results - "Minden, M.D"

Impact of Gene Mutations on Survival with Azacitidine or Conventional Care Regimens (CCR) in Older Patients with Acute Myeloid Leukemia by Tang, L, Dolnik, A, MacBeth, K.J, Dombret, H, Seymour, J.F, Minden, M.D, Stone, R.M, Beach, C.L, Döhner, H, Bullinger, L

Get full text

Do quality of life or physical function at diagnosis predict short-term outcomes during intensive chemotherapy in AML? by Timilshina, N., Breunis, H., Brandwein, J.M., Minden, M.D., Gupta, V., O'Neill, S., Tomlinson, G.A., Buckstein, R., Li, M., Alibhai, S.M.H.

“…Intensive chemotherapy (IC) used to treat acute myeloid leukemia (AML) is associated with toxicity, particularly in older adults. Emerging data suggest that…”
Get full text

Azacitidine Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes by Döhner, H, Vyas, P, Seymour, J.F, Santini, V, Stone, R.M, Minden, M.D, Al-Ali, H.K, del Castillo, T. Bernal, Morrill, J, Songer, S, Weaver, J, Skikne, B.S, Beach, C.L, Dombret, H

Get full text

Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study by Seymour, J.F, Buckstein, R, Santini, V, Döhner, H, Stone, R.M, Minden, M.D, Kuo, C.Y, Ben-Yehuda, D, Bargay, J, Songer, S, Weaver, J, Beach, C.L, Dombret, H

Get full text

285 A nanomolar-potency small molecule inhibitor of the STAT5 protein by Cumaraswamy, A.A, Lewis, A, Geletu, M, Todic, A, Diaz, D.B, Cheng, X.R, Brown, C.E, Laister, R, Muench, D, Kerman, K, Grimes, H.L, Minden, M.D, Gunning, P.T

Get full text

Long-Term Medical Outcomes and Quality-of-Life Assessment of Patients With Chronic Myeloid Leukemia Followed at Least 10 Years After Allogeneic Bone Marrow Transplantation by KISS, T. L, ABDOLELL, M, JAMAL, N, MINDEN, LIPTON, J. H, MESSNER, H. A

“…Benchmark analysis of patients with chronic myeloid leukemia (CML) alive for more than 10 years after allogeneic bone marrow transplantation (BMT) including…”
Get full text

96 OVERALL SURVIVAL IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML WITH >30% BONE MARROW BLASTS AND POOR-RISK CYTOGENETICS TREATED WITH AZACITIDINE: SUBANALYSIS OF THE AZA-AML-001 STUDY by Döhner, H, Seymour, J.F, Butrym, A, Wierzbowska, A, Selleslag, D, Jang, J.H, Cavenagh, J.D, Kumar, R, Schuh, A.C, Candoni, A, Récher, C, Sandhu, I, del Castillo, T. Bernal, Al-Ali, H.K, Martinelli, G, Falantes, J, Nopenney, R, Stone, R.M, Minden, M.D, McIntyre, H, Songer, S, Lucy, L.M, Beach, C.L, Dombret, H

Get full text

124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY by Seymour, J.F, Döhner, H, Butrym, A, Wierzbowska, A, Selleslag, D, Jang, J.H, Cavenagh, J.D, Kumar, R, Schuh, A.C, Candoni, A, Récher, C, Sandhu, I, del Castillo, T. Bernal, Al-Ali, H.K, Martinelli, G, Falantes, J, Nopenney, R, Stone, R.M, Minden, M.D, McIntyre, H, Songer, S, Lucy, L.M, Beach, C.L, Dombret, H

Get full text

In vivo characterization of human double negatve T cells as a potential novel immunotherapy for AML by Li, X, Schuh, N.W, Joe, B, Chen, W.C, Der, S.D, Ohashi, P.S, Minden, M.D, Dick, J.E, Schuh, A.C, Zhang, L

Get full text

Corrigendum to ‘Older age is associated with similar quality of life and physical function compared to younger age during intensive chemotherapy for acute myeloid leukemia’ [Leuk. Res. 36 (10) (2012) 1241–1248] by Mohamedali, H, Breunis, H, Timilshina, N, Brandwein, J.M, Gupta, V, Minden, M.D, Li, M, Tomlinson, G, Buckstein, R, Alibhai, S.M.H

Get full text

INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia by Dzneladze, I, He, R, Woolley, J F, Son, M H, Sharobim, M H, Greenberg, S A, Gabra, M, Langlois, C, Rashid, A, Hakem, A, Ibrahimova, N, Arruda, A, Löwenberg, B, Valk, P J M, Minden, M D, Salmena, L

“…In this study, we investigated the role of i nositol polyphosphate-4-phosphatase, type-II (INPP4B) in acute myeloid leukemia (AML). We observed that AML…”
Get full text

Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients by Bhimji, A., Bhaskaran, A., Singer, L.G., Kumar, D., Humar, A., Pavan, R., Lipton, J., Kuruvilla, J., Schuh, A., Yee, K., Minden, M.D., Schimmer, A., Rotstein, C., Keshavjee, S., Mazzulli, T., Husain, S.

“…Exhaled breath condensate (EBC) is a noninvasive means of sampling the airways that has shown significant promise in the diagnosis of many disorders. There…”
Get full text

Leukemic Transformation of Philadelphia-Negative Myeloproliferative Neoplasms: Results of a Treatment Algorithm Employing Allogeneic Transplantation Using Related and Unrelated Donors by Kennedy, J.A, Atenafu, E.G, Messner, H, Brandwein, J.M, Craddock, K.J, Lipton, J.H, Minden, M.D, Schimmer, A.D, Schuh, A.C, Yee, K.W, Gupta, V

Get full text

110 - Impact of Gene Mutations on Survival with Azacitidine or Conventional Care Regimens (CCR) in Older Patients with Acute Myeloid Leukemia by Tang, L., Dolnik, A., MacBeth, K.J., Dombret, H., Seymour, J.F., Minden, M.D., Stone, R.M., Beach, C.L., Döhner, H., Bullinger, L.

Get full text

HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis by WONG, W. W.-L, DIMITROULAKOS, J, MINDEN, M. D, PENN, L. Z

“…The statin family of drugs target HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, and have been used successfully in the treatment of…”
Get full text

108 - Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study by Seymour, J.F., Buckstein, R., Santini, V., Döhner, H., Stone, R.M., Minden, M.D., Kuo, C.Y., Ben-Yehuda, D., Bargay, J., Songer, S., Weaver, J., Beach, C.L., Dombret, H.

Get full text

Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts by Theocharides, A P A, Dobson, S M, Laurenti, E, Notta, F, Voisin, V, Cheng, P-Y, Yuan, J S, Guidos, C J, Minden, M D, Mullighan, C G, Torlakovic, E, Dick, J E

“…Historically, our understanding of mechanisms underlying human leukemogenesis are inferred from genetically engineered mouse models. Relatively, few models…”
Get full text

111 - Azacitidine Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes by Döhner, H., Vyas, P., Seymour, J.F., Santini, V., Stone, R.M., Minden, M.D., Al-Ali, H.K., del Castillo, T. Bernal, Morrill, J., Songer, S., Weaver, J., Skikne, B.S., Beach, C.L., Dombret, H.

Get full text

Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy by Merims, S, Li, X, Joe, B, Dokouhaki, P, Han, M, Childs, R W, Wang, Z-Y, Gupta, V, Minden, M D, Zhang, L

“…CD3 + CD56 − , CD4 and CD8 double negative T (DNT) cells comprise 1–3% of peripheral blood (PB) mononuclear cells. Their role in tumor immunity remains largely…”
Get full text

Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia by Sibai, H, Seki, J T, Wang, T Q, Sakurai, N, Atenafu, E G, Yee, K W L, Schuh, A C, Gupta, V, Minden, M D, Schimmer, A D, Brandwein, J M

“…Venous thromboembolism (vte) is a recognized complication in patients treated with asparaginase-containing chemotherapy regimens; the optimal preventive…”
Get full text